EULAR 2024  | REGISTRATION  |  CONTACTS  |  ABSTRACTS


FAQ (FREQUENTLY ASKED QUESTIONS)
 

GENERAL SUBMISSIONS

Submit / login

 

Click on "Submit/Login" button to access the EULAR Congress system to submit your abstract, until 15 January 2024, 23:59 CET.

Click on the boxes below to find your answer.

The regular abstract submission is free of charge.

The presenting author would need to register to the EULAR 2024 Congress and pay the applicable registration fees if the abstract is accepted for presentation.

Notifications will be sent out Mid March at the latest.

It is not possible to select “oral only”, the Scientific Committee will judge the abstracts according to the scientific or clinical value, relevance to EULAR, suitability of methods to aims, conclusions confirmed by objective results, objectivity of statements, description of methods used, ethics, originality of work, standard of English, and overall impression.

Abstract notifications for the regular abstract submission deadline on 15 January are expected to be sent in mid-March 2023 by congress.abs@eular.org to the submitter.

Selected abstracts/posters will be published at the EULAR 2024 Congress event. Online publication is approx. 2 weeks prior to the Congress.

For more details visit congress.eular.org/abstract_submission.cfm

Yes, all abstracts can be amended until the deadline. However, you need to ensure to re-submit it.

Yes, we will send a reminder to submit your abstracts in DRAFT.

Yes, you are required to register to the Congress to present your abstract. Therefore, you will have access to questions submitted by the audience.

EULAR does not issue any additional certificates for accepted abstract for presentation or publication. Please use the official abstract publication, final programme and acceptance letter as a proof sent via email.

 

Content and formatting

Click on the boxes below to find your answer.

No, there is no limit of authors or abstracts.

No, only an author of an abstract can be a presenter.

These sections are automatically appear in the abstract as you will see on the preview page.

Images and figures need to be included in the template you upload.

The inclusion of trade names/brand names is not allowed in the abstract, including statistical programmes or other, unless this is peculiar and adds value to their work. The mentioning of agents/molecules must follow the scientific standard for publications.

55 lines is the recommendation, this will keep the abstract concise and it will not contribute to the character count.

No, multiple-panel figures are not accepted. Only one graph or one image is allowed. Tables turned into image are not allowed either.

Yes, it is allowed to submit several abstracts taken from same study.

Yes, Case reports are permissible.

 

Presentation, Copyrights, Licensing

Click on the boxes below to find your answer.

Abstract accepted for "publication only" at EULAR 2024 means that your abstract will be published in the EULAR Online Archive and Abstract Book in its originally submitted version. No further action is needed from the authors as it is not a poster nor oral presentation. Important to note: EULAR will not accept request from authors to edit their publication.

All accepted abstracts will also be published in a supplement to the Annals of Rheumatic Diseases (ARD).

Abstract presentation guidelines for the EULAR 2024 Congress Scientific Programme are available at congress.eular.org/abstract_presentation.cfm

 

Oral Abstract

Presenters must be physically on-site and arrive in the session room between 15 to 30 minutes before the session starts. Each presenter will have 7 minutes to orally present (no pre-recording will be allowed) and 3 minutes for the Q&A.

Poster Tour Presentations

Presenters must be physically on-site and arrive in the session room between 15 to 30 minutes before the session starts. Poster presenters will have a fixed assigned time to present their poster at the assigned Poster Tour Auditorium. Each presenter will have 3 mins for their poster presentation and 2 mins for the Q&A . (No pre-recorded audio narration will be allowed). Failure to present the abstract onsite may lead to rejection of your work at future EULAR Congresses.

Poster Tours presenters will not be required to be present at the Poster Display stations. But audience can search or view their poster by searching the Poster number in the available TV stations.

Poster View Presentations

Poster presenters will have a fixed assigned time (time and location details are only sent to poster presenting authors) to stand in front of their Poster Station to present for 1 hour. Failure to present the abstract onsite may lead to rejection of your work at future EULAR Congresses.

Oral Abstract presenters can only upload their PPT presentations (slides only, without recording) online onto the EULAR Congress System by 31 May 2024, 23:59 CEST. Uploading new slides onsite in Milan WILL NOT be allowed nor possible.

Poster Tour and Poster View presentations:
presenting authors must submit the PDF version of their posters maximum 2 weeks before the congress, by 31 May 2023, 23:59 CEST. No pre-recording nor audio file needed, ONLY the PDF file is required. Failure to upload 2 weeks before congress may result with the removal of your poster from the congress programme.

The authors retain copyright to their work from the abstract submitted, including oral abstract presentation slides and posters (PDF content).

Please see here for full details of the exclusive licence to publish. Authors may re-use material presented in the abstract in further publications, provided that the source of original publication is included [DOI].

Annals of the Rheumatic Diseases (ARD) is an international peer-reviewed journal covering all aspects of rheumatology, which includes the full spectrum of musculoskeletal conditions, arthritic disease, and connective tissue disorders.

You can find further information under https://ard.bmj.com/ and https://congress.eular.org/abstract_archive.cfm

Yes, QR Code will be allowed on a poster. Please ensure that the link behind the QR code follows these rules:

“QR codes are allowed on all posters for the purpose of disseminating scientific and educational content. The information available using the QR code should be freely accessible and should not require any specific log-in. In agreement with applicable laws, rules regulating restrictions for promotional activities in the context of medical events, QR codes should not give access to company sponsored websites allowing the free access to prescription medicines advertisements.”

Poster presenters will have a fixed assigned time (time and location details are only sent to poster presenting authors) to stand in front of their Poster Station to present for 1 hour. Failure to present the abstract onsite may lead to rejection of your work at future EULAR Congresses.

Below are the official Poster Viewing sessions during EULAR 2024:

Official Poster Viewing Time Slots

  Day, Date Time (CEST) Topics represented
1 Wednesday, 12 June (PM)

15:30 - 16:30 

  • Adaptive, innate Immunity
  • Bone diseases, pathology and animal models
  • COVID-19
  • Crystal diseases, metabolic bone diseases other than osteoporosis
  • Infection-related rheumatic diseases
  • Osteo arthritis, aetiology
  • Osteoporosis
  • Public health, health services research, and health economics
  • RA - prognosis, predictors and outcome
  • Spondyloarthritis
  • Spine, mechanical musculoskeletal problems, local soft tissue disorders
2 Thursday, 13 June (AM)

09:30 - 10:30

  • Epidemiology, risk factors for disease or disease progression
  • Large vessel vasculitis
  • Paediatric rheumatology
  • RA - biological DMARDs
  • Spondyloarthritis - clinical aspects (other than treatment)
  • Systemic sclerosis, myositis and related syndromes - aetiology, pathogenesis and animal models
3 Thursday, 13 June (PM)

14:45 - 15:45 

  • Diagnostics and imaging procedures
  • Epidemiology, risk factors for disease or disease progression
  • Psoriatic arthritis - clinical aspects (other than treatment)
  • SLE, Sjögren’s and APS – treatment, aetiology, pathogenesis and animal models
  • RA - non biologic treatment and small molecules
  • Validation of outcome measures and biomarkers
4 Friday, 14 June (AM)

09:30 - 10:30

  • Adaptive, innate immunity
  • Education and Clinical cases
  • Public health, health services research, and health economics
  • RA - aetiology, pathogenesis and animal models
  • RA - comorbidity and clinical aspects
  • Rehabilitation
  • SLE, Sjögren’s and APS – treatment
  • Small vessel vasculitis
  • Spondyloarthritis – treatment
5 Friday, 14 June (PM)

14:45 - 15:45

  • Osteoarthritis
  • Pain in rheumatic diseases, including fibromyalgia
  • Public Health
  • Scleroderma, myositis and related syndromes
6 Saturday, 14 June (AM)

10:30 - 11:30

  • Clinical Cases - VEXAS
  • Other orphan diseases
  • Psoriatic arthritis – treatment
  • SLE, Sjögren’s and APS - aetiology, pathogenesis and animal models, and clinical aspects (other than treatment)
  • Vasculitis - aetiology, pathogenesis and animal models